Figure 2From: Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST) Cumulative incidence of gastrointestinal GvHD > stage 2 after prophylaxis with budesonid and placebo (p = 0.84). Back to article page